About
Research
Publications
2024
Statins Inhibit Cutaneous Squamous Cell Carcinoma Cells
HACKETT A, COHEN A, RUTENBERG T, HODAK E, MOYAL L, ATZMONY L. Statins Inhibit Cutaneous Squamous Cell Carcinoma Cells. Acta Dermato Venereologica 2024, 104: 25097. PMID: 39185545, PMCID: PMC11367778, DOI: 10.2340/actadv.v104.25097.Peer-Reviewed Original ResearchLB941 KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma
Cernova J, Eskin-Schwartz M, Atzmony L, Samuelov L, De Brito M, Chan J, Aviezer D, Brener E, Lederman R, Mashriki T, Michel D, Barak S, Braiman L, Sprecher E, O’Toole E. LB941 KM-001, a novel TRPV3 inhibitor, demonstrates safety and preliminary efficacy in Phase 1b clinical study for the treatment of palmoplantar keratoderma. Journal Of Investigative Dermatology 2024, 144: s164. DOI: 10.1016/j.jid.2024.06.1114.Peer-Reviewed Original Research412 Persistent cutaneous lesions of darier disease are associated with second-hit somatic variants in ATP2A2 gene
Atzmony L, Zagairy F, Tatour Y, Danial-Farran N, Dodiuk-Gad R, Barak E. 412 Persistent cutaneous lesions of darier disease are associated with second-hit somatic variants in ATP2A2 gene. Journal Of Investigative Dermatology 2024, 144: s71. DOI: 10.1016/j.jid.2024.06.428.Peer-Reviewed Original ResearchPersistent Cutaneous Lesions of Darier Disease and Second-Hit Somatic Variants in ATP2A2 Gene
Atzmony L, Zagairy F, Mawassi B, Shehade M, Tatour Y, Danial-Farran N, Khayat M, Warrour N, Dodiuk-Gad R, Cohen-Barak E. Persistent Cutaneous Lesions of Darier Disease and Second-Hit Somatic Variants in ATP2A2 Gene. JAMA Dermatology 2024, 160: 518-524. PMID: 38536168, PMCID: PMC10974685, DOI: 10.1001/jamadermatol.2024.0152.Peer-Reviewed Original ResearchConceptsSomatic variantsATP2A2 geneDeep sequencingResponse to environmental factorsCopy number variantsRestriction fragment length polymorphismLoss of heterozygosityWhole-exome sequencingChromosomal microarray analysisDarier's diseaseFragment length polymorphismPaired whole exome sequencingPathogenic germline variantsHeterozygous pathogenic germline variantsDD lesionsGenomic characteristicsGenetic analysisGenetic skin disordersGermline variantsSanger sequencingLength polymorphismSkin lesionsTransient lesionsHeterozygous variantsMicroarray analysis
2023
65 Persistent cutaneous lesions of darier disease are associated with second-hit somatic variants in ATP2A2 gene
Atzmony L, Zagairy F, Ziv M, Farran N, Dudiok-Gad R, Barak E. 65 Persistent cutaneous lesions of darier disease are associated with second-hit somatic variants in ATP2A2 gene. Journal Of Investigative Dermatology 2023, 143: s343. DOI: 10.1016/j.jid.2023.09.073.Peer-Reviewed Original ResearchFacial hypopigmentation as an unusual manifestation of Demodex infestation – a case series
Holzman R, Hackett A, Pavlovsky L, Feuerman H, Hodak E, Didkovsky E, Segal R, Atzmony L. Facial hypopigmentation as an unusual manifestation of Demodex infestation – a case series. International Journal Of Dermatology 2023, 62: 1289-1291. PMID: 37162494, DOI: 10.1111/ijd.16703.Peer-Reviewed Original ResearchBiological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapyClinical features in adults with acquired cutis laxa: a retrospective review
O’Connell K, Schaefer M, Atzmony L, Vleugels R, Choate K, LaChance A, Min M. Clinical features in adults with acquired cutis laxa: a retrospective review. British Journal Of Dermatology 2023, 188: 800-816. PMID: 36849736, PMCID: PMC10230959, DOI: 10.1093/bjd/ljad043.Peer-Reviewed Original ResearchConceptsAcquired cutis laxaCutis laxaThorough systemic investigationRare dermatological conditionMedication exposureAdult patientsRetrospective reviewPatient historyDermatological conditionsGenetic predispositionGenetic mutationsPatientsSystemic investigationEnvironmental insultsExposureComorbiditiesEtiologyInsultLaxaSymptomatology
2022
Segmental basaloid follicular hamartomas derive from a post‐zygotic SMO p.L412F pathogenic variant and express hair follicle development‐related proteins in a pattern that distinguish them from basal cell carcinomas
Atzmony L, Ugwu N, Bercovitch LG, Robinson‐Bostom L, Ko CJ, Myung P, Choate KA. Segmental basaloid follicular hamartomas derive from a post‐zygotic SMO p.L412F pathogenic variant and express hair follicle development‐related proteins in a pattern that distinguish them from basal cell carcinomas. American Journal Of Medical Genetics Part A 2022, 188: 3525-3530. PMID: 35972041, PMCID: PMC9669121, DOI: 10.1002/ajmg.a.62951.Peer-Reviewed Original ResearchConceptsBasal cell carcinomaCell carcinomaFollicular hamartomaProliferation indexBasaloid skin tumorsSporadic basal cell carcinomasBasaloid follicular hamartomaKi-67 expressionLow proliferation indexCentral nervous systemWhole-exome sequencingSystemic involvementExpression of hedgehogMultiple lesionsSkin tumorsWnt/beta-catenin pathwayBasaloid lesionsNervous systemVariable involvementPathogenic variantsSegmental distributionPost-zygotic mutational eventSOX-9 expressionNormal tissuesExome sequencingInflammatory linear verrucous epidermal nevus (ILVEN) encompasses a spectrum of inflammatory mosaic disorders
Atzmony L, Ugwu N, Hamilton C, Paller A, Zech L, Antaya R, Choate K. Inflammatory linear verrucous epidermal nevus (ILVEN) encompasses a spectrum of inflammatory mosaic disorders. Pediatric Dermatology 2022, 39: 903-907. PMID: 35853659, PMCID: PMC9712156, DOI: 10.1111/pde.15094.Peer-Reviewed Original ResearchConceptsInflammatory linear verrucous epidermal nevusVerrucous epidermal nevusEpidermal nevusCARD14 mutationsHotspot mutationsLinear verrucous epidermal nevusPathogenesis-directed therapyCohort of patientsErythematous scaly plaquesRare skin diseaseLines of BlaschkoSomatic pathogenic variantsNSDHL mutationsHistopathological evaluationInflammatory disordersScaly plaquesHistopathologic evaluationHistopathological criteriaLinear porokeratosisSkin lesionsAffected skinPatientsSkin diseasesClinical descriptorsHeterogenous group
Clinical Care
Overview
Lihi Atzmony Maoz, MD, specializes in treating advanced skin cancer and genetic skin diseases. Her clinical expertise spans a wide range of skin conditions, allowing her to provide comprehensive care to her patients.
Also an assistant professor of dermatology at Yale School of Medicine, Dr. Atzmony Maoz studies the pathogenesis and treatment of genetic skin diseases, particularly Darier disease and porokeratosis, as well as exploring new treatment modalities for non-melanoma skin cancer. Her dedication to understanding and addressing these conditions helps to advance both medical knowledge and patient care.
Dr. Atzmony Moaz earned her medical degree from Tel Aviv University. She completed her residency at Rabin Medical Center and a postdoctoral fellowship at Yale University.
Clinical Specialties
Dermatology
Fact Sheets
Seborrheic Keratosis
Learn More on Yale MedicineRingworm (Tinea)
Learn More on Yale MedicineBirthmarks
Learn More on Yale MedicineViral Warts
Learn More on Yale Medicine
Yale Medicine News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.